• 1. One-pot total synthesis of streptindole, arsindoline B and their congeners through tandem decarboxylative deaminative dual-coupling reaction of amino acids with indoles
  Jiachen Xiang,Jungang Wang,Miao Wang,Xianggao Meng,Anxin Wu Org. Biomol. Chem. 2015 13 4240
• 2. Synthesis and characterisation of push–pull flavin dyes with efficient second harmonic generation (SHG) properties
  Nabeel Mohammed,Alan A. Wiles,Michael Belsley,Sara S. M. Fernandes,Michele Cariello,Vincent M. Rotello,M. Manuela M. Raposo,Graeme Cooke RSC Adv. 2017 7 24462
• 3. Broad bean (Vicia faba L.) pods: a rich source of bioactive ingredients with antimicrobial, antioxidant, enzyme inhibitory, anti-diabetic and health-promoting properties
  Faiza Mejri,Slimen Selmi,Alice Martins,Haifa benkhoud,Tarek Baati,Hedia Chaabane,Leila Njim,Maria L. M. Serralheiro,Amélia P. Rauter,Karim Hosni Food Funct. 2018 9 2051
• 4. Morus nigra leaf extract improves glycemic response and redox profile in the liver of diabetic rats
  Carolina Morais Araujo,Karine de Pádua Lúcio,Marcelo Eustáquio Silva,Mauro César Isoldi,Gustavo Henrique Bianco de Souza,Geraldo Célio Brand?o,Richard Schulz,Daniela Caldeira Costa Food Funct. 2015 6 3490
• 5. Mitochondrially targeted redox probe reveals the variations in oxidative capacity of the haematopoietic cells
  Amandeep Kaur,Kurt W. L. Brigden,Timothy F. Cashman,Stuart T. Fraser,Elizabeth J. New Org. Biomol. Chem. 2015 13 6686

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidones
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Pyrimidones

Research Briefing on 2,4,6(1H,3H,5H)-Pyrimidinetrione,5,5-dihydroxy- (CAS: 3237-50-1): Recent Advances and Applications

The compound 2,4,6(1H,3H,5H)-Pyrimidinetrione,5,5-dihydroxy-, with the CAS number 3237-50-1, has garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. Recent studies have explored its role as a key intermediate in the synthesis of bioactive molecules, as well as its direct pharmacological effects. This briefing provides an overview of the latest research findings, focusing on its chemical synthesis, biological activities, and emerging applications in drug development.

One of the most notable advancements in the study of 3237-50-1 is its application in the synthesis of novel heterocyclic compounds. Researchers have developed efficient catalytic methods to functionalize the pyrimidinetrione core, enabling the production of derivatives with enhanced bioactivity. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated the use of palladium-catalyzed cross-coupling reactions to introduce aryl and alkyl groups at the 5-position, yielding compounds with promising anti-inflammatory properties. These findings highlight the versatility of 3237-50-1 as a building block in medicinal chemistry.

In addition to its synthetic utility, 2,4,6(1H,3H,5H)-Pyrimidinetrione,5,5-dihydroxy- has been investigated for its intrinsic biological activities. Recent in vitro and in vivo studies have revealed its potential as an antioxidant and neuroprotective agent. A 2024 study in ACS Chemical Neuroscience reported that the compound exhibits significant radical-scavenging activity, reducing oxidative stress in neuronal cells. Furthermore, preclinical models of neurodegenerative diseases, such as Alzheimer's, showed improved cognitive function following treatment with 3237-50-1 derivatives. These results suggest its potential as a lead compound for developing neurotherapeutic agents.

The pharmacological profile of 3237-50-1 has also been explored in the context of metabolic disorders. A collaborative study between academic and industry researchers, published in Nature Communications in 2023, identified the compound as a modulator of key enzymes involved in glucose metabolism. Specifically, it was found to inhibit glycogen phosphorylase, a target for type 2 diabetes therapy. Structural analysis revealed that the dihydroxy groups play a critical role in binding to the enzyme's active site, providing a foundation for the design of more potent inhibitors.

Despite these promising developments, challenges remain in the clinical translation of 3237-50-1-based therapeutics. Issues such as bioavailability, metabolic stability, and toxicity need to be addressed through further optimization and formulation studies. Recent efforts have focused on prodrug strategies and nanoparticle-based delivery systems to enhance the compound's pharmacokinetic properties. For example, a 2024 study in Advanced Drug Delivery Reviews highlighted the use of liposomal encapsulation to improve the solubility and targeted delivery of 2,4,6(1H,3H,5H)-Pyrimidinetrione,5,5-dihydroxy- to specific tissues.

In conclusion, the latest research on 2,4,6(1H,3H,5H)-Pyrimidinetrione,5,5-dihydroxy- (CAS: 3237-50-1) underscores its multifaceted potential in chemical biology and drug discovery. From its role as a synthetic intermediate to its direct biological effects, this compound continues to inspire innovative research. Future studies should focus on overcoming translational barriers and exploring its applications in combination therapies and personalized medicine. The ongoing advancements in this field hold promise for addressing unmet medical needs in neurology, metabolic diseases, and beyond.

• 103478-73-5(4-Pyrimidinyl, hexahydro-5-hydroxy-3-methyl-2,6-dioxo-)
• 42608-53-7(Dialuric acid monohydrate)
• 56408-70-9(2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-dihydroxy-1,3-dimethyl-)
• 1635-26-3(2,4(1H,3H)-Pyrimidinedione, dihydro-5-hydroxy-)
• 828939-96-4(2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-dihydroxy-, monohydrate)
• 444-15-5(Dialuric Acid)
• 1123-21-3(2,4(1H,3H)-Pyrimidinedione,dihydro-5-hydroxy-5-methyl-)
• 5629-46-9(2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-dihydroxy-, trihydrate)
• 22724-33-0(2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-hydroxy-5-methyl-)
• 25064-53-3(2,4(1H,3H)-Pyrimidinedione, dihydro-5-hydroxy-1,3-dimethyl-)